FDA clears Picoway for treatment of pigmented lesions

By Rosie Wilson

The FDA has cleared the PicoWay picosecond laser for treatment on pigmented lesions. Synernon Candela, who manufactures PicoWay, claims that the photo-mechanical impact of the device effectively reduces the appearance of pigmentation.

PicoWay is a dual wavelength device, using 532 nm and 1064 nm wavelengths. The picosecond pulse duration generates ultra-short pulse and high power of laser for use on the skin, which breaks down pigmentation.

The approval follows Picoway’s clearance for the removal of tattoos, which was granted in November 2014.

Amit Meridor, the CEO of Synernon Medical, said:

“The expansion of PicoWay’s FDA clearance to include pigmented lesions further enhances the utility of the system, allowing practitioners to offer this next-generation technology for more of their pigmented-related procedures.”

“It is also indicative of our commitment to add new applications that leverage the PicoWay technology for other treatments. Since launching the product late last year, there has been strong interest in PicoWay and we expect the addition of the pigmented lesion indication will further enhance its attractiveness to customers.”